Precision Medicine Got Kidney Disease Wrong—Until Now episode artwork

EPISODE · Apr 1, 2026 · 42 MIN

Precision Medicine Got Kidney Disease Wrong—Until Now

from Power to the Patients · host Brandon Li

Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.

Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.

NOW PLAYING

Precision Medicine Got Kidney Disease Wrong—Until Now

0:00 42:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Power to the Patients?

This episode is 42 minutes long.

When was this Power to the Patients episode published?

This episode was published on April 1, 2026.

What is this episode about?

Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become...

Can I download this Power to the Patients episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!